Zymeworks gains on FDA nod for study of cancer therapy in humans

Zymeworks

17/06/2024 13:58

** Shares of cancer therapy developer Zymeworks  ZYME.O 
rise 6.42% to $9.62 premarket
    ** Co says the U.S. FDA has given its approval for beginning
clinical trial of its ZW171, a type of antibody for different
types of cancers, in humans
    ** ZYME also expects to seek a regulatory nod to begin
studies on ZW171 in other non-US jurisdictions in H2 2024
    ** ZW171 is a bispecific antibody that is designed to engage
two different types of cells - tumor cells and immune cells
    ** Up to last close, stock down ~13% YTD

 (Reporting by Sriparna Roy in Bengaluru)
 ((Sriparna.Roy@thomsonreuters.com;))